Report on Chinese Enoxaparin Sodium Market, 2018-2022” report
has been added to ResearchAndMarkets.com’s offering.
Low-molecular-weight heparin preparations are gradually replacing
unfractionated heparin preparations because of wider clinical
applications. The main product of low-molecular-weight heparin
preparations is Enoxaparin Sodium which was originally developed by
Aventis (merged with Sanofi later) and approved to be sold in the trade
name of Lovenox in 1993. Sanofi’s Enoxaparin Sodium Injection was
approved by FDA in Oct. 2004, and entered the Chinese market in the
beginning of 2005 with a continuous growth in market size. Its sales
value exceeded CNY 300 million in 2017.
Generic drugs also takes up some market share because the average price
of Sanofi’s products is comparatively high. Many pharmaceutical
enterprises in China have obtained the production permit for Enoxaparin
This market research shows that the Chinese market is dominated by
Sanofi. Other major market players include Hangzhou Jiuyuan Gene
Engineering Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., etc.
In 2017, the top 5 manufacturers took up over 90% market share by sales
value, with Sanofi’s market share reaching approximately 80%. Sanofi’s
market share is gradually flowing to domestic enterprises because of
high average price. It is estimated that Sanofi will have ever smaller
market share in the coming years with more Enoxaparin Sodium
manufacturers entering the market in China.
According to research, as China’s population ages, the incidence of
vascular embolic disease continues to rise. At the same time, as the
incidence of ESRD in China continues to rise, the number of people
receiving hemodialysis is also rising. All these factors have driven the
growth of the Enoxaparin Sodium market. There is still a large growth
potential for the Chinese Enoxaparin Sodium market.
Key Topics Covered
1 Relevant Concepts of Enoxaparin Sodium
2 Analysis on Sales of Enoxaparin Sodium in China, 2013-2017
3 Major Enoxaparin Sodium Manufacturers in China, 2013-2017
4 Prices of Enoxaparin Sodium in China, 2017-2018
5 Prospects of Chinese Enoxaparin Sodium Market, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/72x28c/chinese?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005527/en/